biotech

Female patient on gurney

Is This the Turning Point Puma Biotech Investors Have Waited For?

Puma Biotechnology Inc. (NYSE: PBYI) watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial. Although 2016 has been ...
Read Full Story »
M&A

Why the Relypsa Merger Is a Great Idea

Relypsa Inc. (NASDAQ: RLYP) made a splash in the markets on Thursday after the company announced an acquisition agreement. Although the biotech and pharma industries have been hit hard in ...
Read Full Story »
biotech word cloud

4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside

The week of July 15 may have ended on a soft note, but the week was more importantly a one that brought new highs in the Dow Jones Industrial Average and ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In ...
Read Full Story »
Female patient on gurney

CytRx Crumbles on Late-Stage Whiff

CytRx Corp. (NASDAQ: CYTR) absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results. The company announced the results of an analysis of its global, randomized, ...
Read Full Story »
blue eye

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire PLC (NASDAQ: SHPG) made waves Tuesday morning following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, ...
Read Full Story »
Doctor, Health (pulse) copy

Protagonist Therapeutics Files for IPO

Protagonist Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing, but the offering ...
Read Full Story »
Pills and tablets

Biotechs With Drug Pipelines Closest to Zero Valuation

As biotech valuations and share price remain muted versus historic trends, investors have been evaluating which of the best biotech companies are offering the most upside. Other investors are looking ...
Read Full Story »
Female patient on gurney

Audentes Gears Up for IPO With Updated Pricing

Audentes Therapeutics filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 5 million shares ...
Read Full Story »
doctor

How Badly Analysts Ditched Juno Therapeutics After Clinical Hold

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares sink on Friday after the U.S. Food and Drug Administration (FDA) levied a clinical hold on its leukemia treatment. As a result ...
Read Full Story »
Female patient on gurney

Juno Therapeutics Stumbles Over FDA Clinical Hold

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares sink early on Friday after the U.S. Food and Drug Administration (FDA) levied a clinical hold on its leukemia treatment. The company ...
Read Full Story »
clinical trials

Eleven Biotherapeutics Soars on Investigational Milestone

Shares of Eleven Biotherapeutics Inc. (NASDAQ: EBIO) saw a handy gain early on Friday. The company announced that its Investigational New Drug (IND) application for EBI-031 has become effective. As a ...
Read Full Story »
Female patient on gurney

PTC Therapeutics Wins on New DMD Agreement

PTC Therapeutics Inc. (NASDAQ: PTCT) made waves on Thursday following a development in its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. The company announced in conjunction with NHS England, that it ...
Read Full Story »
Female patient on gurney

Why Flexion Therapeutics Is Adding 3 New Executives to Its Ranks

Flexion Therapeutics Inc. (NASDAQ: FLXN) is shuffling its deck of executives, so to speak, in an announcement that it made early Wednesday morning. The company announced that three new executives ...
Read Full Story »
clinical trials

Insys Soars on Huge FDA Win

Insys Therapeutics Inc. (NASDAQ: INSY) shares made a leap early on Tuesday following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved ...
Read Full Story »